44 results about "Early Therapy" patented technology

The invention belongs to the technical field of biomedical detection, and discloses a Raman spectrum analysis device for quantitative detection of hematologic tumor markers, which comprises a blood collection centrifugal unit with a self-adaptive load regulation mechanism for monitoring blood density and components in real time, centrifugal force and time parameters are automatically adjusted according to the blood density and components; the optical fiber Raman spectrometer is provided with an automatic wavelength calibration system, and an ultrafast laser pulse transmitter and a high-sensitivity photon counting detector are integrated on the optical fiber Raman spectrometer. Raman scattering signals are enhanced by adopting a quantum entanglement light source and a nonlinear optical crystal; according to the invention, the detection capability on low-concentration tumor markers can be obviously improved. Due to the improvement, the device can accurately detect the existence of the tumor marker at the early stage of cancer, and powerful support is provided for early treatment of a patient.

The invention discloses a primer probe group and a kit for joint detection of mycoplasma genitalium, ureaplasma urealyticum and chlamydia trachomatis, and belongs to the technical field of molecular biological detection. The primer probe group comprises a primer probe group A for directly detecting a mycoplasma genitalium mgpB gene, a primer probe group B for directly detecting a ureaplasma urealyticum ureB gene and a primer probe group C for directly detecting a chlamydia trachomatis ompA gene; the kit comprises a PCR (Polymerase Chain Reaction) reaction solution and the primer probe group. Nucleic acid extraction is not needed, the detection cost is greatly reduced, the experiment time is shortened, meanwhile, the specificity and accuracy are still guaranteed, meanwhile, the sensitivity is improved, and the method has wide application prospects in the fields of non-gonococcal genital tract infection main pathogen detection, infertility and prenatal and postnatal care screening and the like. And the kit has important significance on clinical diagnosis, early treatment and prevention of diseases, prevalence and the like.

The invention belongs to the field of intelligent medical treatment, and particularly relates to a method, equipment, medium and program product for predicting RMPP based on lung microvascular changes. The method comprises the following steps: S101, acquiring a CT image of a pediatric MPP patient; s102, the CT image is extracted to obtain a quantitative PBV parameter, the quantitative PBV parameter comprises BV10%, and BV10% refers to the percentage of the blood volume in a blood vessel with the blood vessel cross section area larger than 10 mm < 2 > in the total lung blood volume; and S103, if BV10% is higher than a first threshold value, judging that the pediatric MPP patient develops into a prediction result with high RMPP risk, and otherwise, outputting a prediction result with low RMPP risk. According to the application, the prediction effect on the occurrence and development of the RMPP is found by quantitatively measuring the microvascular change in the CT, and the clinical value of early diagnosis of the RMPP is realized, so that the clinical early treatment is driven.

The invention discloses a method, equipment, a medium and a program product for predicting different progression stages of colorectal cancer. The method is used for predicting different progression stages of colorectal cancer based on the expression quantity of target protein. According to the method, by means of a computer system and equipment, whether a subject suffers from colorectal cancer related diseases or not can be well predicted by detecting the expression level of target protein, different progression stages of the colorectal cancer can be distinguished, a new direction and means are provided for early treatment and effective treatment of the colorectal cancer, and the method is worthy of popularization and application. And the method has practical significance on clinical guidance of colorectal cancer.

The invention provides a marker combination for predicting severe acute pancreatitis and application thereof. Specifically, the invention provides application of a gene, mRNA, cDNA and protein of a risk marker for judging severe acute pancreatitis or a detection reagent of the gene, the mRNA, the cDNA and the protein, and the gene, the mRNA, the cDNA and the protein are used for preparing / establishing a diagnostic reagent or a kit / equipment for judging the occurrence risk of severe acute pancreatitis. Researches show that the severe acute pancreatitis risk marker can be used as a marker for early judgment of whether acute pancreatitis patients develop into severe acute pancreatitis, has high sensitivity and specificity, can quickly diagnose severe acute pancreatitis at a relatively early disease progress stage, and provides powerful assistance for early treatment intervention of diseases.

The invention discloses application of a reagent for detecting a plasma metabolism marker combination in preparation of a product for diagnosing breast cancer, and belongs to the field of breast cancer markers. According to the application of the reagent for detecting the plasma metabolism marker combination in preparing the product for diagnosing the breast cancer, the plasma metabolism marker combination comprises dehydroepiandrosterone sulfate, acylcarnitine 12: 0 and taurodeoxycholic acid. The plasma metabolism marker combination has high specificity, high sensitivity and non-invasiveness when being used for breast cancer detection, so that a subject can conveniently and safely receive detection, and the plasma metabolism marker combination is suitable for screening and detection of large-scale common people and is beneficial to early screening, early diagnosis and early treatment of breast cancer.

A B-cell specific octamer-binding protein 1 super-enhancer ribonucleic acid (BOB1-seRNA) and an application thereof are provided. The nucleotide sequence of the BOB1-seRNA is shown in SEQ ID NO: 1. Through experiments, it further confirms that the BOB1-seRNA is downregulated in patients with coronary heart disease and can be used in preparation of a product for diagnosing or predicting the coronary heart disease. The use of this molecular marker can be used for early diagnosis of the coronary heart disease, which is rapid and effective. It is not only of great significance for early treatment of the coronary heart disease and saving medical costs, but also provides therapeutic targets and important basis for clinical applications such as gene therapy and drug therapy.

The invention discloses a traditional Chinese medicine composition for treating middle and advanced stage tumors. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9-11 parts of ganoderma lucidum slices, 1-3 parts of radix angelicae sinensis, 1-3 parts of cordyceps militaris, 5-7 parts of poria cocos, 1-3 parts of fructus lycii, 2-4 parts of radix astragali, 5-7 parts of polyporus umbellatus, 3-5 parts of ginseng slices and 3-5 parts of exocarpium citri grandis. The traditional Chinese medicine composition has the effects of benefiting qi and nourishing blood, tonifying kidney and spleen, and supporting healthy energy. The traditional Chinese medicine is used for treating qi and blood deficiency syndromes caused by middle and advanced tumors, wherein the syndromes comprise mental exhaustion, limb weakness, body emaciation, pale complexion, inappetence and the like. The traditional Chinese medicine composition can also be used for relieving toxic and side effects after radiotherapy and chemotherapy and early treatment of cancers. The invention further discloses a method for preparing the traditional Chinese medicine composition, the dosage form advantage is remarkable, the preparation process is stable and controllable, and the method is suitable for industrial production.

The application provides application of a modified form of WDHD1, WDHD1 S141 phosphorylation, as a biomarker in preparation of a liver cancer early diagnosis or prognosis reagent. The application also provides a kit for quantitatively or semi-quantitatively detecting a protein, which contains an antibody capable of specifically amplifying the WDHD1 S141 phosphorylation. The application can more effectively preliminarily evaluate and predict the condition of a subject suffering from liver cancer by detecting the expression level of the WDHD1 S141 phosphorylation. The application will help improve the diagnosis accuracy of liver cancer and provide an important basis for early treatment of patients. The kit can be applied to the diagnosis of early, middle and late liver cancer. The application also provides application of the WDHD1 S141 phosphorylation in preparation of a liver cancer treatment drug.

The present disclosure is a telescopic endobronchial stem cell cultivation catheter that comprises a segment catheter (1), a terminal catheter (2), and a respiratory catheter (3) ensuring that ensures the prevention of the progression of COPD and provides early treatment before it progresses to advanced stages, allows the increase of the number of reduced lung parenchyma by means of its inoculation feature in advanced COPD stages, provides the removal of metaplastic cells in the bronchial walls in the application area with the rhythmic inflation-deflation movement by means of the balloons (1.2, 2.2, 3.2) and reduces the risk of future cancer formation, and increases respiratory ventilation by expanding narrowed terminal bronchioles (11) and increasing air flow to the respiratory bronchioles (12).

The invention discloses application of a KCNQ5 molecular marker in preparation of an early depression diagnosis kit, and belongs to the technical field of gene detection. The KCNQ5 gene is screened out through a transcriptomics technology for the first time to serve as a potential marker of early-stage depression, and a new direction and target spot are provided for pathogenesis research of early-stage depression. A high-sensitivity ELISA detection method is adopted, accurate and efficient detection of KCNQ5 gene expression related protein in plasma can be achieved, and the blank of early depression diagnosis kits in the current market is filled. The clinical application of the depression early diagnosis kit developed on the basis of the KCNQ5 gene is helpful for realizing early discovery and early treatment of depression, improves the cure rate and life quality of patients, and has important clinical significance and social value.

The invention relates to the field of tumor molecular diagnosis and precision medicine, in particular to a model for predicting early chemotherapy failure of a DLBCL patient and application of the model. By detecting the ctDNA concentration level of the patient base line and the early treatment period and / or combining clinical characteristic parameters, a multivariable risk assessment algorithm is established, the high-risk patient can be identified in the early treatment period, a reliable basis is provided for individualized treatment, and remarkable clinical and social values are achieved.

The invention provides a Parkinson's disease freezing gait prediction method and device based on eye movement characteristics, equipment and a medium. The method comprises the following steps: acquiring target information corresponding to a target object; the target information comprises target demographic data, target clinical features and target eyeball motion parameters collected at a certain time point, and / or target demographic data, target clinical features and target eyeball motion parameters continuously collected according to a preset frequency within a preset time; and inputting the target information into the target frozen gait prediction model, so that the frozen gait prediction model analyzes and processes the target information to obtain a static frozen gait risk assessment result and / or a dynamic frozen gait risk assessment result corresponding to the target object. According to the scheme, through multi-dimensional integration and collaborative verification of traditional clinical phenotypes and objective indexes of eye movement, non-invasive efficient evaluation of frozen gait risks is achieved, and objective basis and key technical support can be provided for early diagnosis and early treatment of disease subtypes.

The invention discloses a preparation method of a monoclonal antibody for detecting trichophyton rubrum and application of the monoclonal antibody in fungal skin disease detection, and belongs to the field of biological medicine. The monoclonal antibody provided by the invention only has specific reaction with trichophyton rubrum, and has no cross reaction with common fungi such as trichophyton mentagrophytes, epidermophyton flocculent, candida albicans, malassezia and the like and normal flora of a human body, so that a false positive result is effectively avoided. Based on the double-antibody sandwich principle, the detection sensitivity can reach 200 pg / mL level, trace trichophyton rubrum in a clinical sample can be detected, and the positive rate is obviously higher than that of direct microscopic examination. The whole detection process can be completed within 15-20 min and is far faster than fungus culture for several weeks, a rapid diagnosis basis can be provided for doctors, and early treatment is facilitated. The kit provided by the invention has standardized operation steps, does not need complex instruments and special training, and is suitable for popularization and use in clinical laboratories of hospitals at all levels, outpatient clinics of dermatology and even basic medical institutions.

The application provides a modified form of DEPTOR, DEPTOR K106 lactylation, as a biomarker in the preparation of a test agent for the preliminary evaluation or prediction of liver cancer. The application also provides a kit for quantitatively or semi-quantitatively detecting a protein, which contains an antibody capable of specifically binding to DEPTOR K106 lactylation. The application can more effectively preliminarily evaluate and predict whether a subject has a tumor by detecting the expression level of DEPTOR K106 lactylation. The application will help improve the diagnostic accuracy of liver cancer and provide an important basis for early treatment of patients. The kit of the application can be used for the diagnosis of early, medium and late liver cancer.

The present application belongs to the field of intelligent medical treatment, and particularly relates to a method, device, medium and program product for predicting RMPP based on lung microvessel changes. The method comprises the following steps: S101: acquiring CT images of a pediatric MPP patient; S102: extracting the CT images to obtain quantitative PBV parameters, wherein the quantitative PBV parameters comprise BV10%, wherein BV10% refers to the percentage of blood volume in blood vessels with a cross-sectional area greater than 10 mm2 in total lung blood volume; and S103: if BV10% is higher than a first threshold value, determining that the pediatric MPP patient has a high risk of developing into RMPP, otherwise outputting a prediction result that the pediatric MPP patient has a low risk of developing into RMPP. The present application discovers the prediction effect of microvessel changes in CT on the occurrence and development of RMPP by quantitatively measuring the microvessel changes, realizes the clinical value of early diagnosis of RMPP, and thus drives early treatment in the clinic.

The application discloses a plasma metabolic marker composition and a screening method and application thereof, and relates to the technical field of biomedicine. The plasma metabolic marker composition comprises glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-formic acid and phosphatidylethanolamine 36:2p. The metabolic marker composition is significantly different in different cancer types, can distinguish different cancer types of cancer patients, and realizes the detection of pan-cancer. The metabolic marker composition is non-invasive and minimally invasive when used for the detection of pan-cancer, is more suitable for the screening and detection of a large number of ordinary people, has high sensitivity and specificity, is more suitable for the early screening of cancer, and is helpful for the early screening, early diagnosis and early treatment of cancer, and is helpful for improving the survival rate and cure rate of cancer patients.

A vital information measurement data recording notebook is provided that makes it easy to check fluctuations in a user's vital information measurement data for the month in question and enables early treatment of the user's cardiovascular disease to be appropriately performed. [Solution] The vital information measurement data recording notebook has a page with a date display section and a vital information measurement data display section. The date display section displays each date from the first day of each month to the last day of that month, and the vital information measurement data display section is displayed in correspondence with the date display section, allowing the user to enter the user's vital information measurement data for the morning, afternoon, and evening of each date. The vital information measurement data display section allows the entry of vital information measurement data including systolic blood pressure, diastolic blood pressure, pulse rate, and body temperature, and allows the user and / or the user's regular medical institution to view and display the user's vital information measurement data including systolic blood pressure, diastolic blood pressure, pulse rate, and body temperature from the first day of the month to the last day of that month.

The application discloses a kind of based on pathological region relationship modeling cervical TCT image detection device, belong to medical image processing technical field, including: in extracting the multiscale feature of entire cell smear image and extracting the feature of segmented small image block, through the pathological region relationship modeling of these two features, and using attention mechanism to extract key features, using the key features to detect pathological region, improve the detection accuracy, help doctors more accurately and easily find pathological cells and suspected pathological cells, can effectively improve the work efficiency of doctors, provide greater possibility for early treatment of patients.

The present disclosure is a telescopic endobronchial stem cell cultivation catheter that comprises a segment catheter (1), a terminal catheter (2), and a respiratory catheter (3) ensuring that ensures the prevention of the progression of COPD and provides early treatment before it progresses to advanced stages, allows the increase of the number of reduced lung parenchyma by means of its inoculation feature in advanced COPD stages, provides the removal of metaplastic cells in the bronchial walls in the application area with the rhythmic inflation-deflation movement by means of the balloons (1.2, 2.2, 3.2) and reduces the risk of future cancer formation, and increases respiratory ventilation by expanding narrowed terminal bronchioles (11) and increasing air flow to the respiratory bronchioles (12).

The present invention relates to a method for diagnosing or treating cancer using cancer-related fibroblasts. According to the method according to the present invention, cancer, particularly breast cancer and pancreatic cancer, can be more accurately diagnosed by using AKR1C1+ inflammatory fibroblasts and / or mesothelioma-derived fibroblasts, and early treatment is possible on the basis thereof. Thus, the method is expected to be widely used in the medical field.

The invention discloses a plasma metabolism marker combination for distinguishing health from lower limb atherosclerotic obliterans and application of the plasma metabolism marker combination, and belongs to the field of lower limb atherosclerotic obliterans markers. The plasma metabolism marker combination for distinguishing health from lower limb atherosclerotic obliterans comprises dehydroepiandrosterone sulfate, iminodiacetic acid, pyruvic acid and phosphatidylcholine 36: 6. The plasma metabolism marker combination has high specificity and high sensitivity when being used for distinguishing health and lower limb atherosclerotic obliterans, is non-invasive, enables subjects to conveniently and safely receive detection, is suitable for screening and detection of large-scale common people, and has wide application prospects. The kit is beneficial to early screening, early diagnosis and early treatment of the lower limb atherosclerotic obliterans.

The application belongs to the technical field of biomedical detection, and discloses a Raman spectrum analysis device for quantitative detection of blood tumor markers, which comprises a blood collection and centrifugal unit with an adaptive load adjustment mechanism, which is used for real-time monitoring of blood density and composition, and automatic adjustment of centrifugal force and time parameters according to the blood density and composition; a fiber Raman spectrometer equipped with an automatic wavelength calibration system, wherein an ultrafast laser pulse emitter and a high-sensitivity photon counting detector are integrated on the fiber Raman spectrometer; the application enhances the Raman scattering signal by adopting a quantum entangled light source and a nonlinear optical crystal, and can significantly improve the detection capability of low-concentration tumor markers. This improvement enables the device to accurately detect the presence of tumor markers in the early stage of cancer, providing strong support for early treatment of patients.

The present invention belongs to the field of microbiology and specifically relates to a phage composition, its application, and pharmaceutical composition. The phage composition comprises the following phages: ФEBU8, ФECL22, and ФEBU30. The present invention highlights the critical importance of early treatment in the treatment of Enterobacter cloacae bacteremia using a phage cocktail, while prophylactic administration may offer the opportunity to delay treatment and salvage bacteremia.

The invention belongs to the technical field of single-chain antibodies, and provides a human anti-cytomegalovirus single-chain neutralizing antibody scFv-26 and application thereof. The human anti-cytomegalovirus single-chain neutralizing antibody scFv-26 with an amino acid sequence as shown in SEQ ID NO.1 is obtained by constructing a phage display library and carrying out solubilization expression and purification on the antibody. As a novel biological treatment means, the human anti-cytomegalovirus single-chain neutralizing antibody shows a wide application prospect in a plurality of medical fields. Firstly, the compound plays a key role in immunosuppressive people, such as organ transplantation patients, HIV infected people, cancer chemotherapy patients and the like; secondly, the method plays an important role in prevention and control of maternal and infant transmission, can provide early treatment choices for congenital CMV infected infants, and reduces sequelae risks. The immunogenicity is remarkably reduced by the humanized design, and the single-chain structure endows high stability and tissue penetrating power, so that the single-chain structure can be easily developed into a long-acting preparation or an inhalation administration form.

This invention relates to the field of medical diagnostic technology, specifically providing a urine PCR kit for predicting minimal change disease (MND) in adults. The kit for detecting MND in adults provided by this invention contains primer sequences for amplifying miR-98-5p. This invention also provides a kit for distinguishing MND from other kidney diseases in adults, the kit containing primer sequences for detecting the relative expression levels of miR-98-5p, miR-204-5p, and / or miR-194-5p in urine samples. Using the kit provided by this invention for the diagnosis of MND, from morning urine collection to obtaining the final result, only 8-12 hours are required, saving patients valuable time and facilitating early treatment and benefit.

This invention provides a combination of biomarkers for predicting thyroid cancer metastasis and their applications. Specifically, this invention provides the use of genes, mRNAs, cDNAs, proteins, or detection reagents thereof for a combination of risk biomarkers for assessing thyroid cancer metastasis, for the preparation / establishment of diagnostic reagents or kits / devices for assessing the risk of thyroid cancer metastasis. Studies have shown that the combination of thyroid cancer metastasis risk biomarkers can serve as biomarkers for early assessment of thyroid cancer metastasis in patients, exhibiting high sensitivity and specificity. It can rapidly diagnose thyroid cancer metastasis at a relatively early stage of disease progression, providing strong support for early treatment intervention.

The invention provides a marker combination for predicting thyroid cancer metastasis and application thereof. Specifically, the invention provides application of a gene, mRNA, cDNA and protein of the risk marker combination for thyroid cancer metastasis judgment or a detection reagent of the gene, the mRNA, the cDNA and the protein, and is used for preparing / establishing a diagnostic reagent or a kit / equipment for judging the thyroid cancer metastasis occurrence risk. Researches show that the thyroid cancer metastasis risk marker combination can be used as a marker for early judgment of thyroid cancer metastasis of a thyroid cancer patient, has high sensitivity and specificity, can quickly diagnose thyroid cancer metastasis at a relatively early disease progress stage, and provides powerful assistance for early treatment intervention of diseases.

The present application relates to the field of medicine, and more particularly to a kind of drug composition for continuing sinew and setting bone and application thereof, the traditional Chinese medicine composition includes the following components by weight fraction: Rhizoma Drynariae 10-20 parts, Fructus Corni 5-15 parts, Lobelia 5-15 parts, crab shell 5-15 parts, snakeberry 5-15 parts, fresh Oxalis 40-60 parts, sugar candy 15-25 parts, the traditional Chinese medicine composition of the present application is suitable for preparing early treatment of closed fracture external medicine, with the characteristics of curative effect, safe use, compatibility science, dosage form optimization. With "dynamic and static combination, cold and warm counteraction, clearing and tonifying combination" as the core of formula, it has the effects of tonifying kidney and strengthening bone, promoting blood circulation to remove blood stasis, clearing heat and resolving toxin, removing dampness and swelling, swelling and pain relief, continuing sinew and setting bone; It also has simple preparation process, can effectively retain fresh medicine active ingredients, and use specific steps to combine dry powder, fresh medicine juice and sugar candy organically, to make paste with strong adhesion, good moisture retention, easy to apply and can release drug efficacy for a long time.

The invention discloses an esophageal cancer or esophageal intraepithelial neoplasia diagnosis model and application thereof, the diagnosis model comprises the following biomarker combination: FN1, VWF, FBXO34 and ITGA2B, and according to the model, whether a subject suffers from esophageal squamous cell carcinoma or esophageal intraepithelial neoplasia can be accurately diagnosed and predicted. The model has excellent diagnosis efficiency and relatively high sensitivity, and is beneficial to further improving a screening method for early diagnosis of esophageal squamous cell carcinoma, so that the improvement of the cure rate and the prolonging of the survival rate of a patient are promoted; effective technical support is provided for early diagnosis, early treatment, prognosis improvement and death rate reduction of esophageal squamous cell carcinoma.